Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Share-based Compensation (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Share-based Compensation data on record, last reported at $1.7 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 109.54% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $4.0 million, up 19.2%, while the annual FY2024 figure was $3.1 million, 39.05% down from the prior year.
  • Share-based Compensation reached $1.7 million in Q3 2025 per ASMB's latest filing, up from $834000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.0 million in Q4 2022 and bottomed at -$286000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $1.2 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: crashed 105.81% in 2021, then soared 604.55% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $1.9 million in 2021, then grew by 3.5% to $2.0 million in 2022, then crashed by 52.36% to $959000.0 in 2023, then dropped by 21.69% to $751000.0 in 2024, then skyrocketed by 122.37% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $1.7 million in Q3 2025, $834000.0 in Q2 2025, and $712000.0 in Q1 2025.